Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HighField Bio to Start US Trial of Immunoliposome for Solid Tumor Cancers

publication date: Jun 15, 2023

HighField Bio, a Hangzhou company that develops immunoliposomes for cancers, was approved to start a US trial of HF158K1, its drug encapsulated immunoliposome containing doxorubicin to treat refractory solid tumor cancers. The company believes the immunoliposome technology offers the ability to deliver larger doses of active drug and targets tumor cells using multiple antibodies compared to ADC drugs. This allows the drug to use an API that is less toxic than an ADC candidate, but may also increase efficacy because the molecule has larger drug-to-antibody ratios that create wider therapeutic windows, targeting more cancer cells with fewer dose-limiting toxicities. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here